Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cinzia Allegrucci has a total of 196 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Loss of PIWI-interacting RNAs regulation drives the expression of LINE1-derived oncogenic lncRNAs in testicular seminoma

    by Ahmad Zyoud, Ryan P. Cardenas, Nabeelah Almalki, Tinyiko Modikoane, Mohammed Ageeli Hakami, Mansour Alsaleem, Cristina Tufarelli, Nigel P. Mongan, Cinzia Allegrucci

    Background: The development of targeted therapies is an unmet clinical need for testicular cancer, especially for those patients that do not respond to platinum-based therapy. While testicular germ cell tumors (TGCTs) are generally curable, a significant number of patients develop refractory metastatic disease, underscoring an urgent need for the discovery of novel therapeutic targets. Epigenetic dysregulation and activation of LINE1 retrotransposons are frequent in seminoma due to genome hypomethylation. Beyond retrotransposition, LINE1 elements can regulate gene expression through bidirectional promoter activity and generate antisense transcripts. As LINE1 activity is tightly controlled by PIWI-interacting RNAs (piRNAs), we investigated whether disruption of this pathway may contribute to TGCTs tumorigenesis by impacting on the expression of LINE1-derived lncRNAs with oncogenic activity. Results: Through integrated analyses, we identified a novel oncogenic axis involving transposable element (TE)-derived lncRNAs associated with dysregulated piRNA expression. A TGCT-specific piRNA signature was identified and mapping of piRNAs to LINE1 sequences identified piR-hsa-7221 as a transcriptional regulator of the lncRNA CASC9 in seminoma. The effect of piR-hsa-7221 was mediated by binding to a complementary LIPA5 sequence and regulating the expression of CASC9 driven by the LINE1 antisense promoter. Loss of piR-hsa-7221 resulted in CASC9 upregulation and oncogenic activity, which was reduced by CASC9 silencing, leading to decreased cancer cell proliferation and invasion, as well as increased sensitivity to cisplatin treatment. Transcriptomic analysis linked these effects to the regulation of the cell cycle, developmental pathways, extracellular matrix, hormone metabolism and immune responses, with WNT signalling emerging as a key downstream target. Conclusions: This study describes a novel epigenetic mechanism in TGCTs involving piRNA-mediated regulation of LINE1-derived oncogenic lncRNAs. This mechanism provides new insights into seminoma pathogenesis and identifies the piR-hsa-7221 and CASC9 axis, together with associated gene networks as potential biomarkers and therapeutic targets.

  • Open Access

    Species-specific WNT requirements shape somite morphogenesis in mammalian embryo models

    by Charlotte Knight, Luke Simpson, Cinzia Allegrucci, Catherine L.R. Merry, Ramiro Alberio

    Somitogenesis establishes the metameric body plan of the vertebrate embryo and can be recapitulated in vitro using stem cell-based embryo models. Although these systems are well established in individual species, they have rarely been compared across species, leaving unresolved how conserved developmental programmes generate species-specific tissue organisation. Here, we compare somitogenesis in embryo models derived from human, pig, sheep and cow pluripotent stem cells and investigate how WNT signalling and the extracellular matrix regulate axis segmentation. Under identical induction conditions, human and pig models diverge in cell-type composition and morphology, revealing distinct modes of axial elongation. Increasing WNT stimulation restores somite formation in pig models but fails to restore ordered segmentation. Furthermore, each of the four mammalian species requires a different level of WNT stimulation and matrix embedding time for somite formation. Finally, comparative analyses identify species-specific differences in progenitor dynamics. Human models, showing ordered segmentation, retain a posterior mesoderm-producing domain, whereas pig models show rapid depletion of this domain, associated with simultaneous somite formation. Together, these findings reveal species-specific requirements for mammalian somitogenesis in stem cell-derived embryo models and suggest that maintenance of a posterior axial domain contributes to ordered segmentation.

  • Open Access

    Modifying Epigenetic Landscapes to Restore Immune Therapeutic Responses in Triple Negative Breast Cancer

    by Nabeelah Almalki, Mercedes Vázquez-Cantú, Riba Thomas, Tinyiko Modikoane, Mansour Alsaleem, Jenny Persson, Emad Rakha, Nigel P. Mongan, Cinzia Allegrucci

    Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer defined by the absence of estrogen and progesterone receptors, as well as the lack of human epidermal growth factor 2 receptor overexpression. TNBC is associated with early onset, high metastatic potential, therapeutic resistance, and poor clinical outcomes exacerbated by the limited availability of effective targeted therapies. Advances in multi-omics profiling have further stratified TNBC into distinct molecular subtypes, each exhibiting unique genomic, epigenomic, and immune-related features that influence therapeutic responsiveness. This review explores the interplay between TNBC molecular heterogeneity, immune evasion mechanisms, and epigenetic regulation. TNBC demonstrates variable immunogenicity, with tumor-infiltrating lymphocytes serving as important prognostic and predictive biomarkers. However, immune escape commonly occurs through tumor microenvironment remodeling, T-cell exhaustion, cancer stem cell enrichment, and immune checkpoint pathways activation. Although immune checkpoint inhibitors have improved outcomes in selected patients, particularly in combination with chemotherapy, primary and acquired therapeutic resistance remain a significant challenge. Emerging evidence highlights the central role of epigenetic mechanisms in regulating immune-related gene expression and shaping the tumor immune microenvironment. Epigenetic silencing of antigen presentation machinery, interferon signaling pathways, and chemokine expression contributes to immune evasion and immunotherapy resistance. Importantly, pharmacological modulation of epigenetic regulators can restore immune recognition and induce “viral mimicry” through reactivation of endogenous retroelements, thereby enhancing antitumor immunity. Collectively, this review underscores the therapeutic potential of integrating epigenetic therapies with immunotherapy and chemotherapy to overcome immune resistance in TNBC. A deeper understanding of epigenetic-immune interactions may facilitate the development of more precise and effective treatment strategies tailored to TNBC molecular subtypes.

  • Open Access

    Loss of piR-hsa-7221 regulation drives the expression of the LINE1-derived oncogenic lncRNA CASC9 in testicular cancer

    by Ahmad Zyoud, Ryan P Cardenas, Nabeelah Almalki, Tinyiko Modikoane, Mohammed Ageeli Hakami, Mansour Alsaleem, Cristina Tufarelli, Nigel P Mongan, Cinzia Allegrucci

    Testicular germ cell tumours (TGCTs) are the most common cancer in young males and are considered curable if they respond to platinum-based therapy. However, a significant number of refractory patients develop metastatic disease and the lack targeted therapy remains an unmet clinical need. To identify novel therapeutic targets, we investigated the epigenetic instability of TGCTs and characterised novel oncogenic gene networks regulated by transposable elements (TEs)-derived long noncoding RNAs (lncRNAs) which are controlled by PIWI-interacting RNAs (piRNAs). A TGCT-specific piRNA signature was identified by bioinformatics analysis of the The Cancer Genome Atlas (TCGA) TGCT dataset and analysis of piRNAs mapped to active LINE1 sequences identified piR-hsa-7221 as a transcriptional regulator of the lncRNA CASC9 in seminoma tumours. We show that piR-hsa-7221 binds to a complementary LINE1 LIPA5 sequence and regulates the expression of CASC9 driven by the LINE1 antisense promoter. Therefore, loss of piR-hsa-7221 drives the upregulation and oncogenic activity of CASC9, which as is impaired after silencing, leading to reduced cancer cell proliferation and invasion, as well as increased sensitivity to cisplatin treatment. These effects are associated with the regulation of the cell cycle, developmental pathways, extracellular matrix, hormone metabolism and immune responses, highlighting WNT signalling as a significant downstream target. Therefore, this novel epigenetic mechanism provides new insights into the role of piRNA-mediated regulation of oncogenic lncRNAs derived from active transposable elements. Importantly, the identification of piR-hsa-7221 and the lncRNA CASC9, together with the associated gene networks highlights novel therapeutic targets for the treatment of seminoma TGCTs.


  • Open Access

    NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2

    by Ryan P Cardenas, Ahmad Zyoud, Alan McIntyre, Ramiro Alberio, Nigel P Mongan, Cinzia Allegrucci

    Background: Testicular germ cell tumours (TGCTs) represent a clinical challenge; they are most prevalent in young individuals and are triggered by molecular mechanisms that are not fully understood. The origin of TGCTs can be traced back to primordial germ cells that fail to mature during embryonic development. These cells express high levels of pluripotency factors, including the transcription factor NANOG which is highly expressed in TGCTs. Gain or amplification of the NANOG locus is common in advanced tumours, suggesting a key role for this master regulator of pluripotency in TGCT stemness and malignancy. Methods: In this study, we analysed the expression of microRNAs (miRNAs) that are regulated by NANOG in TGCTs via integrated bioinformatic analyses of data from The Cancer Genome Atlas and NANOG chromatin immunoprecipitation in human embryonic stem cells. Through gain-of-function experiments, MIR9-2 was further investigated as a novel tumour suppressor regulated by NANOG. After transfection with MIR9-2 mimics, TGCT cells were analysed for cell proliferation, invasion, sensitivity to cisplatin, and gene expression signatures by RNA sequencing. Results: For the first time, we identified 86 miRNAs regulated by NANOG in TGCTs. Among these, 37 miRNAs were differentially expressed in NANOG-high tumours, and they clustered TGCTs according to their subtypes. Binding of NANOG within 2 kb upstream of the MIR9-2 locus was associated with a negative regulation. Low expression of MIR9-2 was associated with tumour progression and MIR9-2-5p was found to play a role in the control of tumour stemness. A gain of function of MIR9-2-5p was associated with reduced proliferation, invasion, and sensitivity to cisplatin in both embryonal carcinoma and seminoma tumours. MIR9-2-5p expression in TGCT cells significantly reduced the expression of genes regulating pluripotency and cell division, consistent with its functional effect on reducing cancer stemness. Conclusions: This study provides new molecular insights into the role of NANOG as a key determinant of pluripotency in TGCTs through the regulation of MIR9-2-5p, a novel epigenetic modulator of cancer stemness. Our data also highlight the potential negative feedback mediated by MIR9-2-5p on NANOG expression, which could be exploited as a therapeutic strategy for the treatment of TGCTs.


  • Open Access

    Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression

    by Nehal M. Atallah, Maria Haque, Cecily Quinn, Michael S. Toss, Shorouk Makhlouf, Asmaa Ibrahim, Andrew R. Green, Mansour Alsaleem, Catrin S. Rutland, Cinzia Allegrucci, et al.


  • Open Access

    Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness

    by Rinad Mahmoud, Paloma Ordóñez-Morán, Cinzia Allegrucci

    The Triple Negative Breast Cancer (TNBC) subtype is known to have a more aggressive clinical course compared to other breast cancer subtypes. Targeted therapies for this type of breast cancer are limited and patients are mostly treated with conventional chemo- and radio-therapies which are not specific and do not target resistant cells. Therefore, one of the major clinical challenges is to find compounds that target the drug-resistant cell populations which are responsible for reforming secondary tumours. The molecular profiling of the different TNBC subtypes holds a promise for better defining these resistant cells specific to each tumour. To this end, a better understanding of TNBC heterogeneity and cancer stemness is required, and extensive genomic analysis can help to understand the disease complexity and distinguish new molecular drivers that can be targeted in the clinics. The use of persister cancer cell-targeting therapies combined with other therapies may provide a big advance to improve TNBC patients’ survival.


  • Open Access

    Intrinsic and Extrinsic Factors Impacting Cancer Stemness and Tumor Progression

    by Alexey Ponomarev, Zarema Gilazieva, Valeriya Solovyeva, Cinzia Allegrucci, Albert Rizvanov

    Tumor heterogeneity represents an important limitation to the development of effective cancer therapies. The presence of cancer stem cells (CSCs) and their differentiation hierarchies contribute to cancer complexity and confer tumors the ability to grow, resist treatment, survive unfavorable conditions, and invade neighboring and distant tissues. A large body of research is currently focusing on understanding the properties of CSCs, including their cellular and molecular origin, as well as their biological behavior in different tumor types. In turn, this knowledge informs strategies for targeting these tumor initiating cells and related cancer stemness. Cancer stemness is modulated by the tumor microenvironment, which influences CSC function and survival. Several advanced in vitro models are currently being developed to study cancer stemness in order to advance new knowledge of the key molecular pathways involved in CSC self-renewal and dormancy, as well as to mimic the complexity of patients’ tumors in pre-clinical drug testing. In this review, we discuss CSCs and the modulation of cancer stemness by the tumor microenvironment, stemness factors and signaling pathways. In addition, we introduce current models that allow the study of CSCs for the development of new targeted therapies.


  • Open Access

    A 3D Heterotypic Breast Cancer Model Demonstrates a Role for Mesenchymal Stem Cells in Driving a Proliferative and Invasive Phenotype

    by Amarnath Pal, Jennifer C. Ashworth, Pamela Collier, Catherine Probert, Sal Jones, Eduardo Pernaut Leza, Marian L. Meakin, Alison A. Ritchie, David Onion, Philip A Clarke, et al.

    Previous indirect 2D co-culture studies have demonstrated that mesenchymal stem cells (MSCs) promote breast cancer (BC) progression through secretion of paracrine factors including growth factors, cytokines and chemokines. In order to investigate this aspect of the tumour microenvironment in a more relevant 3D co-culture model, spheroids incorporating breast cancer cells (BCCs), both cell lines and primary BCCs expanded as patient-derived xenografts, and MSCs were established. MSCs in co-cultures were shown to enhance proliferation of estrogen receptor (ER)/progesterone receptor (PR)-positive BCCs. In addition, co-culture resulted in downregulation of E-cadherin in parallel with upregulation of the epithelial-mesenchymal transition (EMT)-relation transcription factor, SNAIL. Cytoplasmic relocalization of ski-related novel protein N (SnON), a negative regulator of transforming growth factor-beta (TGF-β) signalling, and of β-catenin, involved in a number of pathways including Wnt signalling, was also observed in BCCs in co-cultures in contrast to monocultures. In addition, the β-catenin inhibitor, 3-[[(4-methylphenyl)sulfonyl]amino]-benzoic acid methyl ester (MSAB), mediated reduced growth and invasion in the co-cultures. This study highlights the potential role for SnON as a biomarker for BC invasiveness, and the importance of interactions between TGF-β and Wnt signalling, involving SnON. Such pathways may contribute towards identifying possible targets for therapeutic intervention in BC patients.


  • Open Access

    A Case of Identity: HOX Genes in Normal and Cancer Stem Cells

    by Jessica Smith, Ahmad Zyoud, Cinzia Allegrucci

    Stem cells are undifferentiated cells that have the unique ability to self-renew and differentiate into many different cell types. Their function is controlled by core gene networks whose misregulation can result in aberrant stem cell function and defects of regeneration or neoplasia. HOX genes are master regulators of cell identity and cell fate during embryonic development. They play a crucial role in embryonic stem cell differentiation into specific lineages and their expression is maintained in adult stem cells along differentiation hierarchies. Aberrant HOX gene expression is found in several cancers where they can function as either oncogenes by sustaining cell proliferation or tumor-suppressor genes by controlling cell differentiation. Emerging evidence shows that abnormal expression of HOX genes is involved in the transformation of adult stem cells into cancer stem cells. Cancer stem cells have been identified in most malignancies and proved to be responsible for cancer initiation, recurrence, and metastasis. In this review, we consider the role of HOX genes in normal and cancer stem cells and discuss how the modulation of HOX gene function could lead to the development of novel therapeutic strategies that target cancer stem cells to halt tumor initiation, progression, and resistance to treatment.